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Perspectives
Management of Heterotopic Ossification with Bisphosphonates
after Hip Hemiarthroplasty in Patients with Contraindications to
Standard of Care Prophylaxis
Peter V. TumminelW, Steven D. Shapiro^ Vanessa Cooper^, Dr. Christopher Thomas^ Dr.
Haresh Sampathkumar\ Dr. Mohammad Islam^
'New York Medical College, Department of Physical Medicine and Rehabilitation- Metropolitan Hospital Center, 1901 1st Avenue,
New York, NY 10029
Introduction:

Heterotopic Ossification (HO) is the production of bone outside of
normal physiologic location on the skeleton. This is mostly caused
by a disruption of normal bone formation, leading to production
of bone in soft tissue. Some etiologies include, but aren’t limited to,
surgery, neurologic injury, and genetic disease. The effects of HO
can include functional and gait deficits, limited range of motion, and
pain. One of the most common etiologies for the formation of HO is
following a total hip arthroplasty (THA). The rates of HO following
total hip arthroplasty that have been reported are variable (2-90%).'
There are methods to provide HO prophylaxis successfully via
NSAIDs, single dose radiation therapy, or combination therapy.^’^
However, there are no alternative therapies for HO prophylaxis for
patients with contraindications to NSAIDs and radiation therapy.
This report seeks to suggest methods to prevent HO outside stan
dard of care therapies for this subset of patients.
Case Description:

Figure T. Pre-operative left hip radiograph- transcervical neck fracture of femur.

One month post left hip hemiarthroplasty, a 78-year-old Jehovah
Witness man with history of diabetes, hypertension, chronic kidney
disease, anemia, and thrombocytopenia presented with functional
and gait deficits. The patient had sustained femoral neck fracture
after a fall at home secondary to hypertensive encephalopathy. Left
hip X-ray revealed a femoral neck fracture. The patient received a
left total hip arthroplasty, and was subsequently admitted to acute
inpatient rehabilitation.
The patient developed intolerable pain three weeks after his admis
sion to inpatient rehabilitation, and he became non-weight bearing
on his left leg. Prior to this development the patient was able to walk
25-30 feet in therapy. Repeat X-rays were negative. CT without con
trast was performed on the hip at that time which demonstrated left
sided prosthesis with no loosening. The CT also showed scattered
areas of bone formation seen in the soft tissue at the inner and outer
margin of the hip. Heterotopic bone formation was also noted in
volving the piriformis, gemelli muscles, obturator internus, quadratus femorus, distal insertion of the iliopsoas, and gluteus maximus.
Figure 2: Post-operative radiograph of left total hip
arthroplasty.
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Figure 3: Degree of HO three weeks after admission
to acute inpatient rehabilitation (X-ray).
Discussion:

This patient’s symptoms of progressive functional and gait
disturbance due to pain are consistent with HO as demon
strated by CT. The patient was unable to receive NSAIDs for
prophylaxis due to a past medical history of chronic kidney
disease. In addition, the patient had not received radiation
therapy in the recommended perioperative period from 24
hours prior to surgery to 72 hours post-op. The patient’s
past medical history of anemia and thrombocytopenia were
also contraindications to radiation therapy. The patient’s
thrombocytopenia was also a contraindication to low dose
aspirin therapy.
A literature review study had looked into evidence of alter
native therapies for heterotopic ossification prophylaxis and
treatment using a modified Sackett Scale.

Figure 4: Degree of HO three weeks after admission to
acute inpatient rehabilitation (CT).
there may be a safe way to administer bisphosphonates in
patients with mild-moderate CKD to treat HO.
A retrospective study was performed in which the man
agement of five cases with bisphosphonate therapy after
surgical excision of primary HO had prevented the need for
a second surgery. No recurrences were seen in this small
study. Furthermore, none of the patients had side effects
including nephrotoxicity. It is suggested that the bisphos
phonates not only inhibit the mevalonate pathway in
osteoclasts, but also act as an anti-inflammatory by inter
acting with IL-1, IL-6, and TNF.^ The exact mechanism of
HO prevention is unknown, but correlations exist such that
more research should be done with larger sample sizes to
demonstrate the efficacy of bisphosphonates for HO pro
phylaxis and treatment.
Treatment Plan:

Treatment

Bisphosphonate studies show cohort study Level 2 evidence
in the treatment of HO if the diagnosis is made early (3-6
weeks post-op). Bisphosphonates, however, are unlikely to
be a^ effective if treatment is started when radiographs are
positive. There is also a case series Level 4 evidence that bi
sphosphonates stops secondary HO after surgical resection
ofHO.=
Another study was done to assess the potential benefits and
adverse effects of bisphosphonates in CKD patients with
osteoporosis. Results showed that nephrotoxicity and drug
accumulation is uncommon and of little clinical significance
when lower doses of bisphosphonates are used in CKD. It
was demonstrated that bisphosphonates were safe as long as
renal function was closely monitored with administration
in Stage 1-3 CKD for osteoporotic patients.® If bisphospho
nates can be safely used in CKD patients with osteoporosis.

The primary treatment plan in place for this patient was
conservative management. The patient was placed on
passive ROM therapy without additional prophylaxis or
treatment. The use of passive ROM therapy remains con
troversial. Some studies suggest that passive ROM therapy
may increase the incidence of HO due to microtraumas.
However, other studies emphasize the significance of ROM
exercise to maintain mobility and function. A study by Gar
land demonstrated that 64% of affected joints maintained
or gained ROM with joint manipulation and passive ROM
therapy®. The risk/benefit ratio of joint manipulation favors
joint manipulation in patients for HO prophylaxis.
Conclusion:

Heterotopic ossification is a complication that causes
decrease in extremity range of motion and an increase in
patient pain after trauma, neurological injury, or genetic
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disease. Although there are few alternative therapies for
HO prophylaxis and treatment, these studies show some
promise for subsets of patients who have contraindications
to NSAID and radiation therapy. More research is needed
to assess the benefits of these alternative treatments within
therapeutic windows to assess toxicity and adverse effects.
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